Impact of radiotherapy on secondary lung cancer risk and survival in elderly female breast cancer survivors.

IF 4.5 2区医学 Q1 ONCOLOGY

Translational Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-14 DOI:10.1016/j.tranon.2025.102277

Jieming Lu, Zhimin Shen, Xiaoqing Wang, Yanhong Lin, Ziyang Han, Mingqiang Kang

{"title":"Impact of radiotherapy on secondary lung cancer risk and survival in elderly female breast cancer survivors.","authors":"Jieming Lu, Zhimin Shen, Xiaoqing Wang, Yanhong Lin, Ziyang Han, Mingqiang Kang","doi":"10.1016/j.tranon.2025.102277","DOIUrl":null,"url":null,"abstract":"<p><p>This retrospective cohort study using SEER data from 2000 to 2020 examines the impact of radiotherapy on the risk of Secondary Primary Lung Cancer (SPLC) in 224,396 elderly female breast cancer survivors. Patients treated with radiotherapy displayed a 31 % increased SPLC risk compared to those not treated. Utilizing Cox Proportional Hazards and Poisson regression models, the study assessed various factors including age, race, and tumor characteristics. Propensity Score Matching (PSM) was employed to balance cohorts for survival analysis, which revealed that radiotherapy did not negatively impact overall survival despite the increased risk of SPLC. A nomogram was developed to aid clinical decision-making by predicting survival outcomes. The findings advocate for personalized treatment strategies and continuous monitoring to manage potential long-term adverse effects effectively, highlighting the need for a balanced approach in the treatment of breast cancer survivors.</p>","PeriodicalId":23244,"journal":{"name":"Translational Oncology","volume":"52 ","pages":"102277"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783117/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tranon.2025.102277","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This retrospective cohort study using SEER data from 2000 to 2020 examines the impact of radiotherapy on the risk of Secondary Primary Lung Cancer (SPLC) in 224,396 elderly female breast cancer survivors. Patients treated with radiotherapy displayed a 31 % increased SPLC risk compared to those not treated. Utilizing Cox Proportional Hazards and Poisson regression models, the study assessed various factors including age, race, and tumor characteristics. Propensity Score Matching (PSM) was employed to balance cohorts for survival analysis, which revealed that radiotherapy did not negatively impact overall survival despite the increased risk of SPLC. A nomogram was developed to aid clinical decision-making by predicting survival outcomes. The findings advocate for personalized treatment strategies and continuous monitoring to manage potential long-term adverse effects effectively, highlighting the need for a balanced approach in the treatment of breast cancer survivors.

查看原文本刊更多论文

放疗对老年女性乳腺癌幸存者继发肺癌风险及生存的影响。

这项回顾性队列研究使用2000年至2020年的SEER数据，研究了放疗对224396名老年女性乳腺癌幸存者继发性原发性肺癌（SPLC）风险的影响。与未接受放射治疗的患者相比，接受放射治疗的患者SPLC风险增加了31%。利用Cox比例风险和泊松回归模型，研究评估了包括年龄、种族和肿瘤特征在内的各种因素。采用倾向评分匹配（PSM）来平衡队列进行生存分析，结果显示尽管SPLC风险增加，但放疗对总体生存没有负面影响。通过预测生存结果，开发了一种nomogram方法来帮助临床决策。研究结果提倡个性化的治疗策略和持续监测，以有效地管理潜在的长期不良影响，强调了在治疗乳腺癌幸存者时需要采取平衡的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

7.20

自引率

2.00%

发文量

314

审稿时长

6-12 weeks

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.